Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
ADNOC Gas Targets Up to $4B Profit in 2026 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Royal Philips (AS: PHG) reaffirmed its full-year 2026 guidance after reporting stronger-than-expected first-quarter results, driven by solid sales growth, improving profit margins, and continued productivity gains despite tariff pressures and rising costs.
The Dutch health technology company posted Q1 2026 group sales of €3.90 billion, slightly above analyst expectations of €3.88 billion. Comparable sales increased 4%, outperforming the market consensus of 3.4%. Philips also reported an adjusted EBITA margin of 9%, ahead of analyst estimates of 8.4%, reflecting operational improvements and cost-saving initiatives.
CEO Roy Jakobs said Philips delivered a strong start to the year with healthy order growth and disciplined execution in a challenging macroeconomic environment. Comparable order intake rose 6%, supported by strong demand in the Diagnosis & Treatment and Connected Care divisions, particularly in North America and Europe.
Philips’ Personal Health segment delivered the best performance during the quarter, with comparable sales growth of 9%, significantly above analyst forecasts. The division’s adjusted EBITA margin climbed to 15.8%, also exceeding expectations.
The Diagnosis & Treatment business recorded 2% comparable sales growth, slightly below forecasts, but profitability improved sharply with an adjusted EBITA margin of 9.8%. Meanwhile, Connected Care remained the weakest segment, posting a 3% sales increase but suffering margin pressure from tariffs and inflation, resulting in a lower-than-expected 2.9% adjusted EBITA margin.
Income from operations rose to €241 million, while operating cash flow reached €188 million. Free cash flow totaled €28 million during the quarter.
Philips maintained its full-year 2026 outlook, forecasting comparable sales growth between 3% and 4.5%, adjusted EBITA margin of 12.5% to 13%, and free cash flow ranging from €1.30 billion to €1.50 billion.
The company also announced plans to repurchase up to 4 million shares worth approximately €91 million to support long-term incentive programs, with completion expected by the fourth quarter of 2028.
